



HIV Vaccines

March 26–30, 2017 | Sheraton Steamboat | Steamboat Springs, Colorado | USA

Scientific Organizers:

Andrew B. Ward, The Scripps Research Institute, USA

Penny L. Moore, National Institute for Communicable Diseases, South Africa

Robin Shattock, Imperial College London, UK

Part of the Keystone Symposia Global Health Series, supported by the Bill & Melinda Gates Foundation

Despite great progress in preventing and treating HIV, new infections continue to plague communities around the world, and the need for an HIV vaccine is as urgent as ever. Several large cohorts of HIV-infected individuals have enabled tremendous advances over the past five years in understanding immune responses to natural HIV infection. These advances have included the isolation of broad and potent anti-HIV antibodies, defining their developmental pathways, the generation of native-like Env trimers for immunization, and high-resolution structures of the envelope glycoprotein in complex with bnAbs. By 2017, many of these discoveries will have enabled new concepts to transition into human clinical trials, including passive monoclonal antibody therapy and novel immunization approaches. These platforms, incorporating improved technology for monitoring immune responses, will drive major advances in the vaccine field. This HIV Vaccines meeting will present the latest results from human clinical studies, along with the cutting-edge basic science behind such trials to highlight approaches that may lead to an HIV vaccine, and also reveal the molecular underpinnings of B and T cell-mediated immunity.


Session Topics:

- Emerging Data
 - Lessons from Animal Vaccinations
 - B and T- Cells
 - Adjuvants and Delivery Systems
 - Human Clinical Trials
 - Transmission Biology
 - Lessons from Natural Infection
 - Immunogen Platforms
- plus two workshops*

Scholarship Application & Discounted Abstract Deadline: November 29, 2016

Abstract Deadline: January 10, 2017

Discounted Registration Deadline: January 24, 2017



Note: Scholarships are available for graduate students and postdoctoral fellows and are awarded based on the abstract submitted. Global Health Travel Awards are for investigators from low and middle income countries.

Upper image of B12 antibody courtesy of NIAID, NIH

Meeting Hashtag: #KShivvax

www.keystonesymposia.org/17C9

KEYSTONE SYMPOSIA™
on Molecular and Cellular Biology
Accelerating Life Science Discovery

www.keystonesymposia.org/meetings | 1.800.253.0685 | 1.970.262.1230

a 501(c)(3) nonprofit educational organization

KEYSTONE SYMPOSIA

on Molecular and Cellular Biology

HIV Vaccines (C9)

March 26-30, 2017 • Sheraton Steamboat Resort • Steamboat Springs, Colorado, USA

Scientific Organizers: Andrew B. Ward, Penny L. Moore and Robin Shattock

Part of the Keystone Symposia Global Health Series, supported by the Bill & Melinda Gates Foundation.

Global Health Travel Award Deadline: October 25, 2016 / Abstract & Scholarship Deadline: November 29, 2016 / Abstract Deadline: January 10, 2017 / Discounted Registration Deadline: January 24, 2017

SUNDAY, MARCH 26

Arrival and Registration

MONDAY, MARCH 27

Welcome and Keynote Address

***Andrew B. Ward**, The Scripps Research Institute, USA

Nina D. Russell, Bill & Melinda Gates Foundation, USA

HIV Vaccines - The Year in Review

New Paradigms in Active and Passive Immunization

***Andrew B. Ward**, The Scripps Research Institute, USA

Michel C. Nussenzweig, HHMI/Rockefeller University, USA

Passive Protection with 3BNC117

K. Rachael Parks, University of Washington, USA

Short Talk: Optimizing the Expansion of Primary VRC01 Antibody Responses by Germline-Targeting Immunogens

Todd C. Bradley, Duke University Medical Center, USA

Short Talk: Immune Checkpoint Inhibitor Co-Administration with HIV Env Modifies the Antibody Repertoire

Alejandro Balazs, Massachusetts General Hospital, USA

Development of Vectored ImmunoProphylaxis and ImmunoTherapy against HIV Infection

Jonah B. Sacha, Oregon Health & Science University, USA

Cross-Species CMV Vaccination Reveals Viral Determinants for Induction of Non-Classical MHC-E-Restricted T Cells

Workshop 1: Structural and Mechanistic Insights into Neutralization

***Ian A. Wilson**, The Scripps Research Institute, USA

Kimmo Rantalainen, The Scripps Research Institute, USA

Structure of Full-Length HIV Envelope in Complex with PGT151

Raiees Andrabi, The Scripps Research Institute, USA

Glycans as Anchors for Inducing HIV Broadly Neutralizing Antibodies

Sasha Murrell, The Scripps Research Institute, USA

Structural Investigation of A Novel Family of Broadly Neutralizing Antibodies that Target the N332 Supersite in HIV Env

Evan M. Cale, NIAID, National Institutes of Health, USA

Isolation of an HIV-1-Specific Neutralizing Antibody Lineage with Similar Characteristics to the gp41-gp120 Interface-Binding Antibody 35O22

Gwo-Yu Chuang, NIAID, National Institutes of Health, USA

Optimization of HIV-1 Broadly Neutralizing Antibodies by Surface-Matrix Scanning

Till Schoofs, Rockefeller University, USA

Antibody 10-1074 Suppresses Viremia in HIV-1 Infected Individuals

Ryan Meyerhoff, Duke University, USA

Induction of Antibodies Targeting the V3 Glycan Broadly Neutralizing Epitope in Rhesus Macaques using a Synthetic Immunogen

Lessons from Animal Vaccinations

***Rogier W. Sanders**, University of Amsterdam and Weill Cornell Medical College, Netherlands

Paul Kellam, Kymab, UK

Mice with Fully Human Immunoglobulin Loci and their Use for Predictive Vaccine Antigen Discovery

Maria Blasi, Duke University Medical Center, USA

Short Talk: Sequential Immunizations with an Integrase Defective LentiVector Induce Higher Magnitude and More Durable Antibody Responses than DNA and Protein Based Vaccine Regimens

Nancy L. Haigwood, Oregon Health & Science University, USA

Passive and Active Studies in Primate Models to Inform HIV Vaccines

Peter D. Kwong, NIAID, National Institutes of Health, USA

Short Talk: Peptide-Coupled Carrier Proteins to Focus the Immune Response to an HIV-1 Site of Vulnerability

Andrew B. Ward, The Scripps Research Institute, USA

Structures of HIV Neutralizing Antibodies Elicited from Animal Immunization with SOSIP Env Trimers

Poster Session 1

TUESDAY, MARCH 28

B and T Cells

***Barton F. Haynes**, Duke University Medical Center, USA

Gunilla B. Karlsson Hedestam, Karolinska Institutet, Sweden

Individualized Profiling of Germline V Genes and Application to Env Trimer Immunogenicity Studies in NHPs

Thomas B. Kepler, Boston University, USA

B Cell Clonal Dynamics during Sequential Immunizations

Sabrina Helmold, NCI, National Institutes of Health, USA

Short Talk: Dynamics of T Follicular Helper Cells and Germinal Center B Cells over the Course of Vaccination in Rhesus Macaques

Stephen J. Kent, University of Melbourne, Australia

ADCC and Beyond

Colin Havenar-Daughton, La Jolla Institute for Immunology, USA

Short Talk: Germinal Centers Correlate with HIV Trimer-Induced Neutralizing Antibody Induction and Inform Improved Immunization Scheduling for Maximizing HIV Neutralizing Antibody Responses

Marie Pancera, Fred Hutchinson Cancer Research Center, USA

Short Talk: Anti-Idiotypic Antibodies against Inferred Germline b12, a CD4 Binding Site Antibody, as Tools for Detection of Naïve B Cells Expressing Germline b12-like Precursors and Rational Immunogen Design

Hands-On Computer Session on Los Alamos Sequence Database

Adjuvants and Delivery Systems

***Robin Shattock**, Imperial College London, UK

Carl R. Alving, Walter Reed Army Institute of Research, USA

Rational Basis for Creation and Selection of Adjuvant Formulations for HIV-1 Vaccines

KEYSTONE SYMPOSIA

on Molecular and Cellular Biology

HIV Vaccines (C9)

March 26-30, 2017 • Sheraton Steamboat Resort • Steamboat Springs, Colorado, USA

Scientific Organizers: Andrew B. Ward, Penny L. Moore and Robin Shattock

Part of the Keystone Symposia Global Health Series, supported by the Bill & Melinda Gates Foundation.

Global Health Travel Award Deadline: October 25, 2016 / Abstract & Scholarship Deadline: November 29, 2016 / Abstract Deadline: January 10, 2017 / Discounted Registration Deadline: January 24, 2017

Mark T. Orr, Infectious Disease Research Institute, USA
Tailoring Vaccine Responses with Formulated TLR Agonist Adjuvants

James J. Kobie, University of Rochester, Medical Center, USA
Short Talk: IL-33 Enhances the Induction, Durability, and Breadth of the Antibody Response to a DNA/Protein-Based HIV Env Vaccine

Darrell J. Irvine, Massachusetts Institute of Technology, USA
Regulation of the Germinal Center Reaction and Humoral Response by Vaccine Kinetics

Poster Session 2

WEDNESDAY, MARCH 29

Human Clinical Trials

***Gabriella Scarlatti**, Global HIV Vaccine Enterprise, USA

Mark B. Feinberg, IAVI International AIDS Vaccine Initiative, USA
Expediting Ebola Vaccine Development and Implications for HIV Vaccine R&D Efforts

Alberto Cagigi, NIAID, National Institutes of Health, USA
Short Talk: Potential for Immunization with eOD-GT8 to Drive B Cell Responses Toward the Production of CD4bs Antibodies

Barton F. Haynes, Duke University Medical Center, USA
Testing the Concept of B Cell Lineage Immunogen Design for Initiation of Broadly Neutralizing B Cell Lineages in Human Clinical Trials

Kelly E. Seaton, Duke Human Vaccine Institute, USA
Short Talk: Individual-level meta-analysis of HIV-1 Vaccine Elicited Mucosal Antibodies in Human Volunteers

M. Juliana McElrath, Fred Hutchinson Cancer Research Center, USA
Induction of HIV-Specific Immunity with Recent Clinical Vaccine Approaches

Robin Shattock, Imperial College London, UK
DNA Vaccination for Experimental Medicine Trials of HIV Vaccines

Hands-On Computer Session on Los Alamos Immunology Database

Lessons from Infection

***Penny L. Moore**, University of the Witwatersrand and National Institute for Communicable Diseases, South Africa

Thumbi Ndung'u, University of KwaZulu-Natal, South Africa
Antiretroviral Treatment of Acute HIV Infection and the Prospect for a Functional Cure

Christiane Moog, INSERM and Université of Strasbourg, France
Short Talk: Unexpected Antibody Isotypes and Neutralizing Profile in Patients Controlling HIV

Julie M. Overbaugh, Fred Hutchinson Cancer Research Center, USA
Unique Aspects of the Infant HIV-Specific Neutralizing Antibody Response

Alexandra Trkola, University of Zürich, Switzerland
Determinants of bnAb Development

Poster Session 3

THURSDAY, MARCH 30

Broadly Neutralizing Antibodies: Hurdles and Opportunities

***Alexandra Trkola**, University of Zürich, Switzerland

Penny L. Moore, University of the Witwatersrand and National Institute for Communicable Diseases, South Africa
Longitudinal Studies of Neutralizing Antibody Development in the CAPRISA Cohort

Kshitij Wagh, Los Alamos National Laboratory, USA
Short Talk: Env Glycan Holes Negatively Impact Development of Heterologous Neutralization Breadth in HIV-1 Infections

Brandon DeKosky, University of Kansas, USA
Short Talk: High-Throughput Paired Heavy and Light Chain Analyses of HIV Broadly Neutralizing Antibody Lineages

Elise Landais, International AIDS Vaccine Initiative, USA
Broadly Neutralizing Antibodies to HIV-1: Lessons from Protocol C Studies

Wilton B. Williams, Duke University, USA
Short Talk: SHIV-CH505 Infection of Rhesus macaques Recapitulates HIV-1 Env-Antibody Evolution in Humans

Samantha Leigh Grimley, San Diego Biomedical Research Institute, USA
Short Talk: Striking Impact of HIV-1 Envelope Glycoengineering on BnAb Sensitivities

Nicole A. Doria-Rose, NIAID, National Institutes of Health, USA
Tracing Virus-Antibody Co-Evolution of MPER-directed Neutralizing Antibodies

Workshop 2: Testing Vaccine Platforms in Animals

***Richard T. Wyatt**, IAVI Neutralizing Antibody Center at The Scripps Research Institute, USA

Diane L. Bolton, US Military HIV Research Program, WRAIR, USA
Immunogenicity and Efficacy of MVA, gp145 Vaccination Against Heterologous Tier 2 SHIV C Challenge in Rhesus

Qifeng Han, Duke University, USA
HIV gp41 Immunodominance Following gp140 Immunization Occurs in Humans but is Not Detected in Rhesus Macaques

Mattias Forsell, Umeå University, Sweden
Autologous But Not Heterologous Antibodies Negatively Regulate Subunit-Specific Germinal Center B Cell Responses to the HIV-1 Envelope Glycoproteins

Matthias Georg Pauthner, The Scripps Research Institute, USA
Optimized Env Trimer Immunization Parameters Amplify Onset, Magnitude and Consistency of Autologous Tier 2 Neutralizing Antibody Development in Nonhuman Primates

Paola Andrea Martinez, Karolinska Institutet, Sweden
F9, A New Class of Antibody that Neutralizes Autologous Tier 2 Viruses in Rhesus Immunized with Liposome Conjugated Well-Ordered Trimers

Jose Maximiliano Medina-Ramirez, University of Amsterdam, Netherlands
A Native-Like Envelope Trimer with Enhanced Binding of Inferred Germline Precursors of Broadly Neutralizing HIV-1 Antibodies

James E. Voss, The Scripps Research Institute, USA
Reproducible Elicitation of HIV Envelope V2-Apex Focused Neutralizing Antibodies in Rabbits

Immunogen Platforms

KEYSTONE SYMPOSIA

on Molecular and Cellular Biology

HIV Vaccines (C9)

March 26-30, 2017 • Sheraton Steamboat Resort • Steamboat Springs, Colorado, USA

Scientific Organizers: Andrew B. Ward, Penny L. Moore and Robin Shattock

Part of the Keystone Symposia Global Health Series, supported by the Bill & Melinda Gates Foundation.

Global Health Travel Award Deadline: October 25, 2016 / Abstract & Scholarship Deadline: November 29, 2016 / Abstract Deadline: January 10, 2017 / Discounted Registration Deadline: January 24, 2017

***Peter D. Kwong**, NIAID, National Institutes of Health, USA

Jon Steichen, The Scripps Research Institute, USA
HIV Vaccine Design to Target Germline Precursors of N332-Dependent Broadly Neutralizing Antibodies

Neil P. King, University of Washington, USA
Design of Novel Self-Assembling Protein Nanomaterials as Next-Generation Vaccine Scaffolds

Rogier W. Sanders, University of Amsterdam and Weill Cornell Medical College, Netherlands
Inducing HIV-1 Neutralizing Antibodies with Native-Like Envelope Trimers

Meeting Wrap-Up: Outcomes and Future Directions (Organizers)

FRIDAY, MARCH 31

Departure